The National Cancer Institute is funding a U.S. Phase 2/3 trial testing ivonescimab combined with chemotherapy versus standard chemoimmunotherapy in advanced biliary tract cancer. The study design targets response and safety endpoints to determine whether adding ivonescimab can improve outcomes in a setting where options remain limited.